Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Obesity

India's weight-loss drug boom raises questions over healthcare priorities

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns about misuse for cosmetic reasons are growing. Regulators are intervening in advertising. The drugs also have side effects and can lead to weight regain. This boom is impacting pharmaceutical research priorities.

The Economic Times

UK approves Novo weight-loss pill to edge open European market

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatment. Over 10 million people with obesity in the UK now have an alternative to injections. Drugmakers are racing to expand use of these transformative medicines. The market is expected…

The Economic Times

Wegovy weight-loss pills to be available for patients in UK to buy

Regulator approval means patients who meet criteria will be able to purchase tablets with private prescription

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Scientists Unveil a Diabetes and Obesity Pill That Burns Fat Through Muscle — Without Killing Your Appetite or Causing Muscle Loss

Karolinska/Stockholm University published a new obesity-diabetes pill in Cell (June 2026) that activates muscle metabolism to burn fat and lower blood sugar without appetite suppression or muscle loss. Safe in early human trial.

Medical Daily

First ever guidelines released to screen for condition that impacts 9 in 10 Americans

Doctors say earlier screening could help save lives

The Independent UK

Medicare Is About to Cover Weight-Loss Drugs for the First Time — Here's What the GLP-1 Bridge Program Means for Millions of Americans with Obesity

Medicare's GLP-1 Bridge launches July 1, 2026, offering eligible Part D enrollees Wegovy and Zepbound for $50/month — the first-ever Medicare coverage for obesity-specific GLP-1 drugs.

Medical Daily

New daily weight loss pill helps people shed 10 per cent of body weight

The pill doesn’t have the fasting requirements of many other weight loss drugs

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near

Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Yuval Cohen outlined the company’s near-term clinical readout schedule and development plans for its two lead drug candidates during a Jefferies fireside chat hosted by biotech analyst Amin Makarem. Cohen said the Norwood, Massachusetts-based dru

MarketBeat

Why a dad bod isn’t as harmless as it seems

Approximately 100 million Americans live with obesity — a number that could more than double by 2050

The Independent UK

No, regaining weight after losing it won’t permanently damage your metabolism – new research

When it comes to losing weight, the fear of “ruining your metabolism” is widespread. Indeed, many people who have lost weight and then put it back on feel that every failed attempt leaves them worse off than before, with more fat, less muscle, greater hunger, lower energy, and an ever-diminishing…

The Conversation

US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market

Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients ‌with obesity, ⁠at the ⁠American Diabetes Association meeting in New Orleans.

The Economic Times

Experts call for weight loss jabs to be investigated as cancer prevention

Experts from the US examined data on more than 161,000 patients

The Independent UK

Penn Medicine Reports 30% Drop in Breast Cancer Risk with Ozempic and Wegovy

Penn Medicine researchers report a 30% lower breast cancer risk in women using Ozempic and Wegovy, based on a study of 111,646 patients. Findings suggest GLP-1 drugs may play a role in cancer prevention, though experts stress results are observational.

Medical Daily

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity. Patients also experienced substantial weight loss. These findings were shared at an American Diabetes Association conference. Retatrutide targets multiple hormones related to obesity and…

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

Move Over, Ozempic: Scientists Unveiled a New Diabetes Pill That Burns Fat Without Killing Your Appetite — And It Could Be a Breakthrough for Millions of Americans

Researchers at Karolinska Institutet published a study showing a new oral compound activates muscle metabolism to lower blood sugar and torch fat — without nausea, muscle loss, or the side effects plaguing GLP-1 drugs.

Medical Daily

With Nation's Highest Diabetes Rate, San Antonio Faces Major Shift as Medicare Prepares $50 Wegovy Coverage

With diabetes rates among the highest in the U.S., San Antonio could see major change as Medicare's new $50 Wegovy coverage begins July 1, expanding access for eligible residents.

MarketBeat

Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference

Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide. Peter Griffith, executive vice president and chief financial

Medical Daily

From Crisis to Possible Cure Path: San Antonio Battles Highest Diabetes Rates as Wegovy and Medicare (United States) Expansion Offer New Hope

Diabetes care is entering a new era in San Antonio as the Wegovy pill and expanded Medicare coverage offer new hope for preventing and managing diabetes in one of America's hardest-hit cities.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

‘Morally unreasonable’ to tackle childhood obesity with weight loss jabs, Chris Whitty says

The 2024 Health Survey for England found that 15 per cent of children aged two to 15 were living with obesity

The Economic Times

Time to walk and cycle the talk: Unsafe roads and broken footpaths are worsening India’s obesity crisis

Commuting in Indian urban centers is riddled with obstacles, where inadequate sidewalks and hazardous road conditions push people towards cars, resulting in a rise in lifestyle-related health problems. Interestingly, a large number of city trips could easily be made by foot or bike, yet the lack of safe pathways keeps…

The Economic Times

Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight loss

Alkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordable for diabetes and obesity management. The company is the first in India to offer this convenient format. This move intensifies competition in the growing Indian drug market. Alkem aims to expand access…

Clever Dude

The Hidden Side Effect of Weight-Loss Injections That Men Aren’t Talking About

Weight-loss injections continue to reshape conversations around obesity treatment and metabolic health. Men across different age groups report rapid drops in appetite and steady weight loss that once felt difficult to achieve. Clinics highlight improvements in blood sugar control, waist size, and cardiovascular markers.

The Conversation

Can Wegovy move the needle on NZ’s obesity crisis, or simply treat its symptoms?

Even before receiving public funding, Wegovy has drawn much media attention in New Zealand for the dramatic difference it can make for weight loss.

International Business Times UK

Donald Trump Weight Gain: CNN Expert Calls Out Discrepancies in Medical Memo

A new White House medical memo reveals Donald Trump has gained 14 pounds in a year, edging his BMI to the brink of obesity even as his doctor insists he is in 'excellent health'.

International Business Times

Donald Trump's BMI Nears Clinical Obesity In New Medical Report

Donald Trump's recent medical report shows a BMI of 29.7, sparking discussions about his weight and health, despite claims of being in 'excellent health' by his physician.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.